Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • Optimal Care Pathway
    • For Patients
    • For Health Professionals
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • Optimal Care Pathway
    • For Patients
    • For Health Professionals
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » General » Lanreotide rejected by PBAC for listing on PBS for non-functional GEP NETs

Lanreotide rejected by PBAC for listing on PBS for non-functional GEP NETs

  • January 19, 2017
After the November meeting the PBAC rejected the submission for listing of Lanreotide for non functional GEP NETs.

According to the PBAC "Subsequent decisions not to recommend" document,  The PBAC did not recommend the listing of lanreotide for the treatment of non-functional GEP NETs on the basis of unfavourable and uncertain cost-effectiveness at the price proposed by the sponsor.

The Unicorn Foundation CEO Simone Leyden and patient Peter McMenamin had the opportunity to present the patient case for Lanreotide at a consumer hearing to the PBAC on November 1 in Brisbane, we are very grateful to Peter who did an outstanding job representing NET Cancer patients and telling about his experience on the drug and how it was effective for him.

According to the above mentioned document, The PBAC acknowledged and welcomed the many consumer comments received from people living with non-functional GEP-NETs and the input from the Unicorn Foundation. In addition, representatives of the PBAC met with the Unicorn Foundation prior to the PBAC meeting to discuss the clinical place, benefits and side effects of lanreotide for the requested patient population. The Committee recognised the strong support for subsidised access to lanreotide for this condition. 

 According to IPSEN the drug sponsor Whilst Ipsen is disappointed with the decision, we remain committed to working with PBAC to ensure this important indication is made available to Australian patients with GEP-NETs.

We are also committed to ensuring that NET Cancer patients can access drugs that are considered standard care and will keep you updated on any progress. 

To view the full document please see below. 

 https://neuroendocrine.org.au/wp-content/uploads/2020/03/subsequent-decisions-not-to-recommend-2016-11.pdf

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Michael Doyle Live Wake Fundraiser

February 4, 2023

Optimal Care Pathway now available for NETs

January 31, 2023

World Cancer Day 2023

January 10, 2023

Support Groups Christmas Gatherings

December 20, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousNew online chat sessions for NET Patients
NextRegistered charity tickNext

Related Posts

NECA Finalist as NGO of the Year in Prime Awards

We’re thrilled to be announced as one of the finalists in the NGO of The Year category in the 2022 PRIME Awards Australia. The Prime

COVID-19 Information and Resources

A note from our CEO on COVID-19: To our wonderful NET community we stand with you and alongside you as we get through this unprecedented

Expression-of-Interest for consumer participation on Grant Review Committees for the 2022 Priority-driven Collaborative Cancer Research Scheme

Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS) is an innovative, competitive, annual cancer research projects grant funding scheme. The PdCCRS is conducted by Cancer

32 neuroendocrine tumour presentations at ASCO annual scientific conference

The ASCO Annual Conference was held virtually this year from 29 – 31 May 2020 with 32 Neuroendocrine presentations from this meeting delivered orally, by

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative